David Malcom Rodman sold $12k of MLYS
Chief Medical Officer at Mineralys Therapeutics, Inc.. 417 shares at an average of $27.59, traded Feb 17, 2026, filed Feb 17, 2026.
Score components
- +15RoleOfficer
- 0Trade size$12k at market
- 0Share of holdings soldSold 0.9% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.7%, 3m -6.8%, 6m -4.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001672659-26-000013, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | MOption exercise Common Stock10b5-1 | +417 | $15.44 | $6,438 | 44,506 | Feb 17, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -417 | $27.59 | $12k | 44,089 | Feb 17, 2026 |
| Feb 17, 2026 | MOption exercise Stock Optionderivative10b5-1 | -417 | $0.00 | $0 | 5,417 | Feb 17, 2026 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 5Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $193k 7,437 shares | -16% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $59k 2,170 shares | -4% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $200k 7,438 shares | -16% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 416 shares | -1% | |
| 34Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $291k 10,700 shares | -2% | |
| 24Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $557k 20,407 shares | -28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.